Metformin Impurity 13, with the CAS number 847373-57-3, is a chemical compound associated with the pharmaceutical agent metformin, commonly used in the treatment of type 2 diabetes. As an impurity, it may arise during the synthesis or degradation of metformin and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. Impurities like Metformin Impurity 13 are often analyzed for their potential effects on the efficacy and safety of the primary drug. The characterization of such impurities usually involves techniques like high-performance liquid chromatography (HPLC), mass spectrometry, and nuclear magnetic resonance (NMR) spectroscopy to determine their identity, concentration, and impact on the overall formulation. Regulatory agencies require thorough assessment of impurities to ensure that they do not adversely affect the therapeutic outcomes or pose safety risks to patients. Understanding the properties and behavior of Metformin Impurity 13 is essential for maintaining the quality and integrity of metformin-containing medications.

Metformin Impurity 13

847373-57-3: Metformin Impurity 13, with the CAS number 847373-57-3, is a chemical compound associated with the pharmaceutical agent metformin, commonly used in the treatment of type 2 diabetes. As an impurity, it may arise during the synthesis or degradation of metformin and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. Impurities like Metformin Impurity 13 are often analyzed for their potential effects on the efficacy and safety of the primary drug. The characterization of such impurities usually involves techniques like high-performance liquid chromatography (HPLC), mass spectrometry, and nuclear magnetic resonance (NMR) spectroscopy to determine their identity, concentration, and impact on the overall formulation. Regulatory agencies require thorough assessment of impurities to ensure that they do not adversely affect the therapeutic outcomes or pose safety risks to patients. Understanding the properties and behavior of Metformin Impurity 13 is essential for maintaining the quality and integrity of metformin-containing medications.

CAS 847373-57-3

Metformin Impurity 13

Metformin Impurity 5

Ref: ST-EA-CP-M3024